E Parellada

Summary

Country: Spain

Publications

  1. ncbi request reprint Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations
    Eduard Parellada
    Clinical Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, University of Barcelona, Spain
    Psychopharmacol Bull 40:82-100. 2007
  2. ncbi request reprint [Hikikomori or simple schizophrenia?]
    Maria Gariup
    Med Clin (Barc) 130:718-9. 2008
  3. ncbi request reprint Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study
    Eduard Parellada
    Department of Psychiatry, Hospital ClínicVillarroel 170, Universitat de Barcelona, E 08036 Barcelona, Spain
    Psychiatry Res 130:79-84. 2004
  4. ncbi request reprint Risperidone in the treatment of patients with delirium
    Eduard Parellada
    Psychiatry and Psychology Clinic Institute, Hospital Clinic i Provincial de Barcelona, University of Barcelona, C Villaroel 170, 08036 Barcelona, Spain
    J Clin Psychiatry 65:348-53. 2004
  5. doi request reprint Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
    Eduard Parellada
    Clinic Schizophrenia Program, Hospital Clinic de Barcelona, University of Barcelona, CIBERSAM, Spain
    Int Clin Psychopharmacol 25:149-54. 2010
  6. ncbi request reprint Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
    E Parellada
    Clinic Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neurosciences, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain
    J Psychopharmacol 19:5-14. 2005
  7. ncbi request reprint Clinical experience and management considerations with long-acting risperidone
    Eduard Parellada
    Clinic Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, University of Barcelona, Spain
    Curr Med Res Opin 22:241-55. 2006
  8. ncbi request reprint Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint
    M Bernardo
    Department of Psychiatry, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    Psychiatry Res 107:87-97. 2001
  9. doi request reprint Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes
    S Mas
    Department of Pathological Anatomy, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain
    Pharmacogenomics J 12:255-9. 2012
  10. ncbi request reprint Role of the cingulate gyrus during the Wisconsin Card Sorting Test: a single photon emission computed tomography study in normal volunteers
    A M Catafau
    Department of Nuclear Medicine, Hospital Clinic, University of Barcelona, Spain
    Psychiatry Res 83:67-74. 1998

Detail Information

Publications19

  1. ncbi request reprint Long-acting injectable risperidone in the treatment of schizophrenia in special patient populations
    Eduard Parellada
    Clinical Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, University of Barcelona, Spain
    Psychopharmacol Bull 40:82-100. 2007
    ..To determine the effectiveness of long-acting risperidone, the literature was reviewed to evaluate the efficacy and safety of long-acting risperidone in these populations. The impact of race was also considered...
  2. ncbi request reprint [Hikikomori or simple schizophrenia?]
    Maria Gariup
    Med Clin (Barc) 130:718-9. 2008
  3. ncbi request reprint Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study
    Eduard Parellada
    Department of Psychiatry, Hospital ClínicVillarroel 170, Universitat de Barcelona, E 08036 Barcelona, Spain
    Psychiatry Res 130:79-84. 2004
    ..Our data indicate a lack of sex differences in striatal D2 receptor binding in drug-naive schizophrenic patients and do not support previous reports of left lateralized striatal asymmetry in male schizophrenic patients...
  4. ncbi request reprint Risperidone in the treatment of patients with delirium
    Eduard Parellada
    Psychiatry and Psychology Clinic Institute, Hospital Clinic i Provincial de Barcelona, University of Barcelona, C Villaroel 170, 08036 Barcelona, Spain
    J Clin Psychiatry 65:348-53. 2004
    ..The aim of this study was to evaluate the efficacy and safety of risperidone in the treatment of patients with delirium...
  5. doi request reprint Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
    Eduard Parellada
    Clinic Schizophrenia Program, Hospital Clinic de Barcelona, University of Barcelona, CIBERSAM, Spain
    Int Clin Psychopharmacol 25:149-54. 2010
    ..Serious AEs were reported by 384 (8%) patients. This study confirms good safety, tolerability, and efficacy with RLAI in routine clinical practice...
  6. ncbi request reprint Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
    E Parellada
    Clinic Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neurosciences, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain
    J Psychopharmacol 19:5-14. 2005
    ..Direct initiation of RLAI is well accepted by patients. RLAI might represent a novel option for patients in the early phases of psychosis...
  7. ncbi request reprint Clinical experience and management considerations with long-acting risperidone
    Eduard Parellada
    Clinic Schizophrenia Program, Department of Psychiatry, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, University of Barcelona, Spain
    Curr Med Res Opin 22:241-55. 2006
    ..Risperidone is the first atypical anti-psychotic available in a long-acting injectable formulation...
  8. ncbi request reprint Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint
    M Bernardo
    Department of Psychiatry, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    Psychiatry Res 107:87-97. 2001
    ..In this regard, SPECT studies including baseline and endpoint examinations should be encouraged...
  9. doi request reprint Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes
    S Mas
    Department of Pathological Anatomy, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain
    Pharmacogenomics J 12:255-9. 2012
    ..No significant correlations were observed with regard to CYP3A5 and ABCB1. We find that, despite not knowing patients' metabolic status, clinicians modify risperidone dosage in order to obtain the best therapeutic option...
  10. ncbi request reprint Role of the cingulate gyrus during the Wisconsin Card Sorting Test: a single photon emission computed tomography study in normal volunteers
    A M Catafau
    Department of Nuclear Medicine, Hospital Clinic, University of Barcelona, Spain
    Psychiatry Res 83:67-74. 1998
    ..In addition, no order effect was found in this study. These findings illustrate the advantage of independently evaluating the cingulate gyrus and the prefrontal cortex in SPECT studies of frontal cognitive function...
  11. doi request reprint Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients
    A M Catafau
    Experimental Medical Sciences, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Barcelona, Spain
    J Psychopharmacol 22:882-94. 2008
    ..D(2)RO patterns over time differ between AP. These results should be considered for accurate interpretation of D(2)RO measurements, proper design of studies and optimization of drug regimens for patients on AP treatment...
  12. doi request reprint A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms
    P Gasso
    Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain
    Pharmacogenomics J 9:404-10. 2009
    ..AP-induced EPS remains a serious public health problem. Our finding of a common SNP (rs167771) in the DRD3 gene provides a strong new candidate gene for risperidone-induced EPS...
  13. ncbi request reprint Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait
    Jose J Mateos
    Nuclear Medicine Department, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
    Psychopharmacology (Berl) 191:805-11. 2007
    ..In our previous study, we observed lower DAT binding in a group of first-episode schizophrenic patients after short-term treatment with risperidone, compared with age-matched healthy controls...
  14. ncbi request reprint Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study
    Francisco Lomena
    Department of Nuclear Medicine, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    Psychopharmacology (Berl) 172:165-9. 2004
    ....
  15. ncbi request reprint Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
    Hans Jurgen Moller
    Department of Psychiatry, University of Munich, Germany
    Int Clin Psychopharmacol 20:121-30. 2005
    ..Direct initiation of RLAI was effective and well tolerated. RLAI provides an advancement in the treatment options available for a wide range of patients requiring long-term antipsychotic therapy...
  16. ncbi request reprint Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics
    Amalia Lafuente
    Dep Farmacología y Química Terapéutica, Universidad de Barcelona, IDIBAPS, Casanova 143, E 08036 Barcelona, Spain
    Schizophr Res 90:115-22. 2007
    ..Impaired dopamine transporter (DAT) function may be involved in antipsychotic (AP)-induced extrapyramidal symptoms (EPS). A polymorphism involving a variable number of tandem repeats (VNTR) has been described in the DAT gene (SLC6A3)...
  17. doi request reprint Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy
    Anna Crescenti
    Department of Pharmacology, School of Medicine, IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Exp Pharmacol Physiol 35:807-11. 2008
    ..4, 95% CI 1.13-18, permutated P value 0.003) and the risk of suffering EPS. 3. These results suggest that the CYP2D6 genotype may be a contributory factor in the development of EPS in patients undergoing AP therapy...
  18. pmc Glucose abnormalities in the siblings of people with schizophrenia
    Emilio Fernandez-Egea
    Hospital Clinic Schizophrenia Program, Department of Psychiatry, Neuroscience Institute, Hospital Clinic, Barcelona, Spain
    Schizophr Res 103:110-3. 2008
    ..Previous studies have also suggested that there is an increased prevalence of diabetes in the relatives of schizophrenia probands...